Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial.
Doyen J, Poudenx M, Gal J, Otto J, Guerder C, Naghavi AO, Gérard A, Leysalle A, Cohen C, Padovani B, Ianessi A, Schiappa R, Chamorey E, Bondiau PY. Doyen J, et al. Among authors: poudenx m. Radiother Oncol. 2018 May;127(2):239-245. doi: 10.1016/j.radonc.2018.03.024. Epub 2018 Apr 9. Radiother Oncol. 2018. PMID: 29650404 Clinical Trial.
Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, Guigay J, Benzaquen J, Marquette CH, Berthet JP, Mouroux J, Schiappa R, Padovani B, Hofman P, Otto J. Bouhlel L, et al. Among authors: poudenx m. Bull Cancer. 2020 Sep;107(9):946-958. doi: 10.1016/j.bulcan.2020.04.019. Epub 2020 Jul 6. Bull Cancer. 2020. PMID: 32646604
Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial.
Poudenx M, Bondiau PY, Chamorey E, Venissac N, Otto J, Pourel N, Castelnau O, Tessier E, De Surmont Salasc B, Berdah JF, Pop D, Michel C, Mouroux J. Poudenx M, et al. Oncology. 2012;83(6):321-8. doi: 10.1159/000342081. Epub 2012 Sep 13. Oncology. 2012. PMID: 22986621 Free article. Clinical Trial.
Skeletal muscle metastasis from non-small cell lung cancer.
Pop D, Nadeemy AS, Venissac N, Guiraudet P, Otto J, Poudenx M, Mouroux J. Pop D, et al. Among authors: poudenx m. J Thorac Oncol. 2009 Oct;4(10):1236-41. doi: 10.1097/JTO.0b013e3181b24509. J Thorac Oncol. 2009. PMID: 19641472 Free article.
Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study.
Chardin D, Paquet M, Schiappa R, Darcourt J, Bailleux C, Poudenx M, Sciazza A, Ilie M, Benzaquen J, Martin N, Otto J, Humbert O. Chardin D, et al. Among authors: poudenx m. J Immunother Cancer. 2020 Jul;8(2):e000645. doi: 10.1136/jitc-2020-000645. J Immunother Cancer. 2020. PMID: 32709713 Free PMC article.
Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer.
Sumodhee S, Guo L, Bouhlel L, Picard A, Otto J, Naghavi AO, Richier Q, Lévy A, Bondiau PY, Poudenx M, Passeron T, Lacour JP, Montaudié H, Doyen J. Sumodhee S, et al. Among authors: poudenx m. Cancer Radiother. 2022 Nov;26(8):1045-1053. doi: 10.1016/j.canrad.2022.04.005. Epub 2022 Aug 1. Cancer Radiother. 2022. PMID: 35927166
18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns.
Humbert O, Cadour N, Paquet M, Schiappa R, Poudenx M, Chardin D, Borchiellini D, Benisvy D, Ouvrier MJ, Zwarthoed C, Schiazza A, Ilie M, Ghalloussi H, Koulibaly PM, Darcourt J, Otto J. Humbert O, et al. Among authors: poudenx m. Eur J Nucl Med Mol Imaging. 2020 May;47(5):1158-1167. doi: 10.1007/s00259-019-04573-4. Epub 2019 Nov 23. Eur J Nucl Med Mol Imaging. 2020. PMID: 31760467
67 results